ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
宜明昂科生物醫藥技術（上海）股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 1541)

VOLUNTARY ANNOUNCEMENT

FIRST PATIENT DOSED IN THE PHASE IB/II CLINICAL TRIAL OF IMM2510 IN COMBINATION WITH CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF NSCLC

This announcement is made by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Group.

The board (the "**Board**") of directors ("**Directors**", and each a "**Director**") of the Company is pleased to announce that the first patient has been successfully dosed in the Phase Ib/II clinical trial of IMM2510 in combination with chemotherapy for the first-line treatment of non-small cell lung cancer (NSCLC). Following a safety run-in, the Company plans to enroll first-line patients in the aforesaid clinical trial and anticipates releasing initial clinical data, including data from the first-line patients with NSCLC, as early as the second half of 2025.

The clinical data from the Phase I dose-escalation study of IMM2510 demonstrated encouraging signs of efficacy: several patients with advanced solid tumors, who had failed multiple lines of treatments, achieved partial response (PR) following IMM2510 treatment. As of December 31, 2024, over 100 patients had been enrolled in the Phase I/II clinical trials of IMM2510 monotherapy. Favorable tolerability and promising preliminary PR signals were observed across multiple solid tumor indications, including patients with repeated treatment failures, such as NSCLC, triple-negative breast cancer (TNBC) and soft-tissue sarcoma (STS).

Phase Ib/II clinical studies of IMM2510 are currently being actively advanced across multiple solid tumor indications, both as a monotherapy and in combination with various treatment modalities.

- In November 2023, the Company successfully dosed the first patient in the Phase II clinical trial of IMM2510 monotherapy for the treatment of advanced or relapsed and refractory (R/R) solid tumors such as lung cancer, TNBC, STS and renal cancer.

- In July 2024, the Company successfully dosed the first patient in the Phase Ib clinical trial of IMM2510 in combination with IMM27M for the treatments of advanced solid tumors such as hepatocellular carcinoma.

- On December 27, 2024, the Company successfully dosed the first patient in the Phase Ib clinical trial of IMM2510 in combination with chemotherapy for the first-line treatment of NSCLC.

- In December 2024, the investigational new drug (IND) application for the Phase Ib clinical trial of IMM2510 in combination with IMM01 (Timdarpacept) for the treatment of advanced solid tumors, such as gastric cancer, head and neck cancer, was accepted by the National Medical Products Administration of the People's Republic of China (NMPA).

ABOUT IMM2510

IMM2510, independently developed by the Group, is a bispecific molecule with a mAb-Trap structure targeting vascular endothelial growth factor (VEGF) and programmed cell death ligand 1 (PD-L1). IMM2510 can inhibit angiogenesis, leading to tumor shrinkage, and sensitize tumor cells to immune responses, while activating T cells, NK cells, and macrophages via the blockade of PD-L1/programmed cell death protein 1 (PD-1) interaction and the induction of Fc-mediated antibody-dependent cellular cytotoxicity (ADCC)/ antibody-dependent cellular phagocytosis (ADCP) activity.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market, IMM2510, successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
宜明昂科生物醫藥技術（上海）股份有限公司
Tian Wenzhi
Chairman and Executive Director

Shanghai, the PRC, January 13, 2025

As at the date of this announcement, the Board of Directors comprises (i) Dr. Tian Wenzhi, Mr. Li Song and Ms. Guan Mei as executive Directors; (ii) Dr. Xu Cong as non-executive Director; and (iii) Dr. Zhenping Zhu, Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat as independent non-executive Directors.